0001562180-24-000970.txt : 20240202 0001562180-24-000970.hdr.sgml : 20240202 20240202161001 ACCESSION NUMBER: 0001562180-24-000970 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240131 FILED AS OF DATE: 20240202 DATE AS OF CHANGE: 20240202 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Burke Steven Keith CENTRAL INDEX KEY: 0001619834 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36352 FILM NUMBER: 24591473 MAIL ADDRESS: STREET 1: 82 WILLIS ROAD CITY: SUDBURY STATE: MA ZIP: 01776 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Akebia Therapeutics, Inc. CENTRAL INDEX KEY: 0001517022 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 208756903 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 245 FIRST STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-871-2098 MAIL ADDRESS: STREET 1: 245 FIRST STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 4 1 primarydocument.xml PRIMARY DOCUMENT X0508 4 2024-01-31 false 0001517022 Akebia Therapeutics, Inc. AKBA 0001619834 Burke Steven Keith C/O AKEBIA THERAPEUTICS, INC 245 FIRST STREET CAMBRIDGE MA 02142 false true false false SVP, Chief Medical Officer false Common Stock 2024-01-31 4 A false 202200.00 0.00 A 735687.00 D Common Stock 2024-02-01 4 S false 24311.00 1.68 D 711376.00 D Stock Option (Right to buy) 1.68 2024-01-31 4 A false 303300.00 0.00 A 2034-01-31 Common Stock 303300.00 303300.00 D The restricted stock units were granted by the Issuer pursuant to its 2023 Stock Incentive Plan. One third of the restricted stock units will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date. Includes 1,500 shares of the Issuer's common stock purchased on June 30, 2023 and 1,500 shares of the Issuer's common stock purchased on December 29, 2023, each under the Issuer's Amended and Restated 2014 Employee Stock Purchase Plan. This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on January 31,2023. The options were granted by the Issuer pursuant to its 2023 Stock Incentive Plan. The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the reporting person's continued service with the Issuer on each vesting date. /s/ Carolyn Rucci, attorney-in-fact for Steven K. Burke 2024-02-02